1. Home
  2. AMTB vs KALV Comparison

AMTB vs KALV Comparison

Compare AMTB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$22.51

Market Cap

922.1M

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.78

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
KALV
Founded
1979
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
1.0B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
AMTB
KALV
Price
$22.51
$26.78
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$23.67
$32.60
AVG Volume (30 Days)
202.2K
5.4M
Earning Date
04-23-2026
07-09-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.44
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$8.29
$185.42
Revenue Next Year
$7.67
$59.23
P/E Ratio
$51.17
N/A
Revenue Growth
N/A
495.66
52 Week Low
$15.62
$9.83
52 Week High
$24.38
$26.85

Technical Indicators

Market Signals
Indicator
AMTB
KALV
Relative Strength Index (RSI) 44.27 74.77
Support Level $21.98 $14.25
Resistance Level $22.75 $26.85
Average True Range (ATR) 0.59 0.07
MACD -0.10 -0.19
Stochastic Oscillator 48.74 70.45

Price Performance

Historical Comparison
AMTB
KALV

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: